Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial

Hsu, Chiun; Kuo, Sung‐Hsin; Hu, Fu‐Chang; Cheng, Ann‐Lii; Shih, Jin‐Yuan; Yu, Chi; Lin, Chia‐Chi; Huang, T; Yang, Pan‐Chyr; Yang, Changhui

doi:10.1016/j.lungcan.2008.03.010

Cited by 14 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy may be attributed to the fact that, contrary to the study by Liu et al (44), the present study was restricted to patients with ATC and included various chemotherapy regimens. In agreement with the data of the present study, no obvious association between topo-II expression and response to chemotherapy was detected in lung cancer (24–26,45). Instead of predicting chemosensitivity, high levels of topo-II expression may serve as a specific marker of cell proliferation, invasive behavior and unfavorable prognosis.…”

Section: Discussionsupporting

confidence: 93%

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

et al. 2017

View full text Add to dashboard Cite

Class III β-tubulin (TUBB3) and Topoisomerase-II (topo-II) are considered to be the predictors of therapeutic efficacy and outcome in several types of human neoplasm. However, whether TUBB3 or topo-II may predict the response to combination chemotherapy and prognosis in patients with advanced thymic carcinoma (ATC) remains unclear. The aim of the present study was to investigate the prognostic significance of TUBB3 and topo-II expression levels in ATC. A total of 34 patients with ATC who received combination chemotherapy were enrolled in the present study. Immunohistochemical analysis was used to examine the expression of TUBB3, topo-II and Ki-67 in tumor specimens obtained by surgical resection or biopsy. TUBB3 and topo-II were highly expressed in 38 and 53% of the tumors, respectively. Progression-free survival (PFS) was significantly shorter in patients with high levels of TUBB3 compared with those with low levels of TUBB3 (P<0.01), whereas no significant difference in PFS between patients with high and low topo-II expression levels was observed (P=0.31). Patients with overexpression of TUBB3 or topo-II exhibited significantly shorter overall survival rates (OS) compared with those patients with low levels of expression of these proteins (TUBB3; P=0.01, topo-II; P=0.01). Multivariate analysis demonstrated that a high level of TUBB3 expression was an independent unfavorable prognostic factor for OS, and a high level of topo-II expression tended to correlate with poor prognosis without statistical significance. Additionally, a subset analysis demonstrated that the treatment with taxanes, but not topo-II inhibitors, tended to prolong OS in patients with TUBB3 overexpression and there was significant survival advantage of chemoradiotherapy over chemotherapy in patients with topo-II overexpression. It was revealed that an enhanced expression of TUBB3 or topo-II was clearly associated with clinical outcomes in patients with ATC who received combination chemotherapy, including taxanes or topo-II inhibitors, suggesting the prognostic significance of these markers.

show abstract

Section: Discussionsupporting

confidence: 93%

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although the final efficacy data are pending, initial results are promising, with 37% ORR and 71% DCR versus 28% ORR and 59% DCR for arms A and B, respectively. The results obtained in the present study with Lipoplatin/gemcitabine compare favorably to those obtained with cisplatin/gemcitabine, and the latter combination has yielded efficacy and toxicity figures not inferior to the already published studies in the literature evaluating this combination in advanced NSCLC [46,47,48] The commonest toxicities observed were grades I and II myelotoxicity, nevertheless significant grades III and IV myelotoxicities were observed in the cisplatin/gemcitabine combination treatment. These toxicities occurred mostly in single infusions and responded well to hemopoietic factors.…”

Section: Discussionsupporting

confidence: 76%

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

et al. 2010

View full text Add to dashboard Cite

“…One significant predictor of treatment withdrawal was previous anthracycline use. Two prior studies in this medical center used epirubicin as part of first-line chemotherapy for advanced NSCLC [16,17]. Fourteen patients enrolled in the above two trials received cisplatin-based combination chemotherapy as their second-line therapy and weekly docetaxel as their third-line treatment.…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial

Cited by 14 publications

References 53 publications

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers

Contact Info

Product

Resources

About